Avaxia Biologics raises $6.4M to test new IBD drug

[Igor_Passau]

The new funding will be used to finance a first-in-human Phase 1b clinical trial of the company’s new oral anti-TNF antibody, AVX-470, for the treatment of ulcerative colitis. TNF, tumor necrosis factor, helps regulate immune cells and is often responsible for systemic inflammation associated with several diseases, including IBD. AVX-470 is designed to act locally in the gastrointestinal tract to suppress inflammation, combining the efficacy of existing anti-TNF therapeutics with a lower risk of dangerous immunosuppressive side effects.

full article
http://www.bizjournals.com/boston/b...ign=Feed:+vertical_47+(Telecom+Industry+News)